A groundbreaking clinical study conducted by Intermountain Health in Salt Lake City, Utah, suggests that a simple daily supplement could dramatically reduce the risk of recurrent heart attacks in survivors. Researchers found that vitamin D3 supplementation significantly lowered the likelihood of a second heart attack among those who had previously experienced one.
The findings, presented at the 2025 American Heart Association (AHA) Scientific Sessions in New Orleans, revealed that targeted treatment to achieve optimal vitamin D3 levels could cut the recurrence risk by as much as 50%.
Inside the TARGET-D Trial
The study, known as the TARGET-D trial, enrolled 630 patients between April 2017 and May 2023. All participants had suffered a heart attack within the prior month. Remarkably, 85% of them had insufficient vitamin D3 levels at the outset.
Participants were divided into two groups: one received targeted vitamin D3 supplementation, while the other did not. The goal was to raise vitamin D blood concentrations above 40 nanograms per milliliter (ng/mL)—a level believed to offer cardiovascular protection.
Those in the treatment group underwent annual blood tests to ensure that their vitamin D levels remained optimal. More than half of them required an initial dose of 5,000 international units (IU) per day, notably higher than the 600–800 IU generally recommended for healthy adults.
Significant Results and No Adverse Effects
By March 2025, after several years of follow-up, 107 participants experienced a major cardiac event. However, those receiving vitamin D3 supplementation had a markedly lower rate of recurrence. Lead investigator Dr. Heidi May, a cardiovascular epidemiologist at Intermountain Health, reported that no adverse effects were observed, even at higher dosages.
“These results are exciting and encouraging,” Dr. May said. “While more research is needed to confirm our findings, maintaining normal vitamin D levels has long been associated with a reduced risk of coronary artery disease, heart failure, and stroke.”
Globally, it is estimated that two-thirds of people have insufficient vitamin D levels, often due to limited sun exposure and modern indoor lifestyles.
Expert Perspectives on the Findings
Independent experts have welcomed the results with cautious optimism. Dr. Bradley Serwer, an interventional cardiologist and chief medical officer at VitalSolution in Maryland, emphasized that the cardiovascular benefits of vitamin D have long been recognized, though prior studies struggled to prove its protective impact against heart attacks.
“Previous research often used standard replacement dosages that were too low to restore healthy vitamin D levels,” Dr. Serwer explained. “This study’s targeted approach makes its findings particularly compelling.”
However, he cautioned that these results may primarily apply to high-risk cardiac patients and not necessarily to individuals with normal vitamin D levels. “Further research is essential to determine whether similar benefits extend to lower-risk populations,” he added.
Vitamin D: More Hormone Than Vitamin
Dr. Marc Siegel, a senior medical analyst and professor of medicine, noted that vitamin D acts “more like a hormone than a vitamin,” influencing numerous organ systems—including the heart. “Deficiency in vitamin D contributes to inflammation and blood clotting, which increase cardiovascular risk,” he said. “Maintaining normal levels helps reduce the incidence of coronary artery disease, heart failure, and stroke.”
A Promising Step Toward Prevention
While more studies are needed to confirm the causal link between vitamin D3 supplementation and reduced cardiac recurrence, the TARGET-D trial represents a significant advance in cardiovascular research. The findings suggest that ensuring adequate vitamin D levels—through supplements or safe sun exposure—could serve as a simple, cost-effective strategy to improve heart health for millions of survivors worldwide.
Related topics
